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AbstrACt
Objectives The aim of this study was to compare 
effectiveness and safety of low-strength and high-strength 
direct oral anticoagulants (DOACs) with warfarin in the 
Australian Veteran population.
Design Sequential cohort study using inverse probability 
of treatment weighting (IPTW) and propensity score 
matching. Initiators of high-strength (apixaban 5 mg, 
dabigatran 150 mg, rivaroxaban 20 mg) and low-strength 
DOACS (apixaban 2.5 mg, dabigatran 110 mg, rivaroxaban 
15 mg) were compared with warfarin initiators.
setting Australian Government Department of Veterans’ 
Affairs claims database.
Participants 4836 patients who initiated oral 
anticoagulants (45.8%, 26.0% and 28.2% on low-strength, 
high-strength DOACs and warfarin, respectively) between 
August 2013 and March 2015. Mean age was 85, 75 
and 83 years for low-strength, high-strength DOACs and 
warfarin initiators, respectively.
Main outcome measures One-year risk of hospitalisation 
for ischaemic stroke, any bleeding event or haemorrhagic 
stroke. Secondary outcomes were 1-year risk of 
hospitalisation for myocardial infarction and death.
results Using the IPTW method, no difference in risk of 
ischaemic stroke or bleeding was found with low-strength 
DOACs compared with warfarin. As a class, no increased 
risk of myocardial infarction was found for low-strength 
DOACs, however, risk was elevated for apixaban (HR 
2.25, 95% CI 1.23 to 4.13). For high-strength DOACs, no 
difference was found for ischaemic stroke compared with 
warfarin, however, there was a significant reduction in 
risk of bleeding events (HR 0.63, 95% CI 0.44 to 0.89) and 
death (HR 0.40, 95% CI 0.28 to 0.58). Propensity score 
matching showed no difference in risk of ischaemic stroke 
or bleeding.
Conclusion We found that in the practice setting both 
DOAC formulations were similar to warfarin with regard to 
effectiveness and had no increased risk of bleeding.
IntrODuCtIOn
Direct oral anticoagulants (DOACs) were 
subsidised on the Pharmaceutical Bene-
fits Scheme (PBS) in Australia in 2013 for 
prevention of stroke or systemic embolism 
in patients with atrial fibrillation (AF). At the 
time of listing, there was uncertainty around 
their cost–benefit advantage over warfarin, 
their potential bleeding risk and the limited 
strategies available to control overanticoag-
ulation.1 Since listing, DOACs have gained 
significant market share with one-third of 
people commencing anticoagulant therapy 
initiated on a DOAC.2 This is partly because 
treatment with warfarin is complex due to 
anticoagulant response being highly variable 
between and within patients, and the require-
ment for regular monitoring to avoid overan-
ticoagulation or therapeutic failure. DOACs 
offer an alternative treatment option, with 
fixed dosing based on clinical characteris-
tics such as age, weight and renal function. 
However, there are concerns about the fixed 
dosing recommendations with DOACs, and 
the lack of the ability to monitor anticoagula-
tion, particularly for the lower doses which are 
recommended for patients who typically have 
greater variability in drug concentrations and 
response. This concern is exacerbated by the 
relatively low proportion of patients in clin-
ical trials3 who were on low-dose products for 
rivaroxaban and apixaban (22% and 4.9% in 
rivaroxaban and apixaban trials, respectively).
We aimed to compare the effective-
ness and safety of low-strength and high-
strength formulations of DOACs to warfarin. 
strengths and limitations of this study
 ► A strength was the use of a sequential cohort ap-
proach to minimise channelling bias.
 ► A strength was that the results were stratified by 
direct oral anticoagulant (DOAC) strength.
 ► Unable to determine the dose of DOAC consumed 
by the patient.
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Low-strength and high-strength products were analysed 
separately because different DOAC formulations are 
recommended for distinct patient subgroups and dose 
adjustment is required in patients at increased risk of 
bleeding.
MethODs
A balanced sequential cohort study design was employed 
to minimise channelling bias, a type of selection bias 
that may occur when a new medicine enters the market.4 
Five cohorts representing sequential 4 monthly calendar 
intervals were established based on the date of initia-
tion of oral anticoagulant therapy (index dispensing); 
cohort 1: patients initiated between 1 August 2013 and 
30 November 2013, cohort 2: 1 December 2013 and 31 
March 2014, cohort 3: 1 April 2014 and 31 July 2014, 
cohort 4: 1 August 2014 and 30 November 2014, cohort 
5: 1 December 2014 and 31 March 2015.
The Australian Government Department of Veterans’ 
Affairs (DVA) administrative claims database was used for 
this analysis. These data include all medicines dispensed 
under the PBS, and all medical, hospital and allied health 
services claimed by veterans. DVA maintains a client 
file including, date of birth, gender, date of death and 
family status for veterans, spouses and their dependents. 
Prescriptions are coded according to WHO’s Anatomical, 
Therapeutic Chemical (ATC) classification system5 and 
PBS item codes.6 Hospitalisations are coded according 
to International Classification of Disease, 10th Revision 
Australian Modification (ICD-10AM) codes.7
Patients were included if they initiated anticoagulation 
during the study period. Patients were considered as initi-
ators if they had no dispensing of any oral anticoagulant 
in the 12 months prior to the index dispensing. Partic-
ipants were included if they were 18 years or older, not 
in residential aged care and had DVA enrolment for at 
least 12 months prior to the index dispensing. DVA enrol-
ment means that participants were eligible for all health 
services subsidised by DVA. Patients were excluded if they 
had an aortic valve procedure in the 12 months prior to 
initiating treatment (procedure codes: 3848800, 3848801, 
3848900, 3848901, 3855301, 3855303, 3855601, 3855603, 
3856201, 3856203, 3856501, 3856503).
Exposure to DOAC was identified using PBS item 
codes for the indication of AF (see online supplementary 
appendix A) and classified as either low-strength (apix-
aban 2.5 mg, dabigatran 110 mg, rivaroxaban 15 mg) or 
high-strength (apixaban 5 mg, dabigatran 150 mg, rivar-
oxaban 20 mg). Warfarin was identified using the ATC 
code B01AA03.8 Individuals in each cohort were followed 
for up to 12 months from their index dispensing or until 
they switched to another anticoagulant or died; which-
ever came first.
The primary effectiveness outcome was hospital admis-
sion for stroke (ischaemic or unspecified stroke) and 
the primary safety outcomes were hospitalisation for any 
bleeding event (gastrointestinal or other bleeding events) 
or haemorrhagic stroke (ICD10 codes provided in online 
supplementary appendix B). Secondary outcomes were 
hospitalisation for myocardial infarction (MI) or death.
An inverse probability of treatment weighting (IPTW) 
approach was used to compare the rate of outcomes sepa-
rately for low-strength DOACs with warfarin and high-
strength DOACs with warfarin. This method measures the 
average treatment effect (ATE), it is the average effect at 
the population level that would be seen if all individuals 
received the treatment compared with if none of these 
individuals received the treatment. Within each calendar 
cohort, logistic regression was used to estimate the prob-
ability, or propensity, of DOAC treatment compared with 
warfarin conditional on patient covariates measured at 
the time of treatment initiation.9 Separate propensity 
score (PS) models were created for high-strength DOAC 
compared with warfarin, and for low-strength DOAC 
compared with warfarin within each calendar cohort. 
Additionally, a separate PS model was built for each indi-
vidual product. There were 31 covariates included in the 
PS models that were established a priori by clinicians 
as variables potentially associated with treatment selec-
tion and outcomes (table 1 and online supplementary 
appendix A). Each subject was weighted by the inverse 
of their probability of receiving the treatment that they 
actually received, calculated using the PS model.10 This 
process reweights the DOAC and warfarin treatment 
groups to create a pseudo population where the baseline 
covariates are independent of treatment. To reduce vari-
ance in treatment effects arising from individuals with 
large weights (PS near 0 or 1),11 weights were stabilised 
by multiplying the prevalence of DOAC treatment in 
participants dispensed a DOAC and one minus the prev-
alence of DOAC treatment in those dispensed warfarin. 
To limit the size of extreme weights, we then truncated 
the weights at the 5th and 95th percentile. For those, 
with weights below the 5th and above the 95th percen-
tile, their weights were adjusted to those of the 5th or 
95th percentiles. Balance in baseline covariates between 
DOAC and warfarin treatment groups, before and after 
weighting was compared using standardised differences 
using a 10% (0.1) threshold to signify imbalance.10 12
In the final analysis, a combined calendar cohort was 
created from cohorts 2–5. Cohort 1 was excluded as a 
Product Familiarisation Program (PFP)13 that provided 
company-sponsored access to dabigatran prior to PBS 
listing meant that we were unable to distinguish initiators 
of dabigatran from prevalent users from the PFP.
Cox proportional hazards model was used for all 
analyses.
We undertook a post hoc analysis for the secondary MI 
endpoint, where we stratified results by baseline aspirin 
use. A sensitivity analysis using PS matching was also 
undertaken, which measures the ATE, which is the effect 
on the outcome if individuals in the population were 
randomly assigned to treatment. Within each calendar 
cohort, DOAC initiators were matched on a 1:1 basis on 

































pen: first published as 10.1136/bm





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































pen: first published as 10.1136/bm





4 Pratt NL, et al. BMJ Open 2019;9:e026486. doi:10.1136/bmjopen-2018-026486
Open access 
on warfarin, using a calliper width of 0.05. Balance was 
measured using standardised differences between base-
line covariates of the matched cohort. For each matched 
PS cohort, we applied a robust sandwich variance esti-
mator to account for the matched design.15
All analyses were conducted using SAS V.9.4 (SAS).
Patient and public involvement
Patients and public were not directly involved in this 
research.
results
A detailed flow chart of the cohort selection process is 
presented in figure 1. Table 1 details the baseline character-
istics of patients by exposure group. Compared with those 
initiated on warfarin, patients initiated on low-strength 
DOACs were older, had a higher congestive heart failure, 
hypertension, Age (≥ 65 = 1 point, ≥ 75 = 2 points), 
diabetes, and stroke/TIA (2 points) (CHADS2) score, 
fewer hospitalisations in the 60 days prior to initiation, 
lower prevalence of prior hospitalisation for ischaemic 
stroke, haemorrhagic stroke, MI and bleeding events and 
were more likely to be initiated treatment by a specialist. 
Compared with patients initiated on warfarin, patients 
initiated on high-strength DOACs were younger, had 
lower CHADS2 score, less hospitalisation in the 60 days 
prior to initiating therapy, lower prevalence of prior stroke 
or bleed and were more likely to be initiated treatment by 
a specialist. Based on standardised differences, for both 
the low-strength and high-strength groups, characteris-
tics were more similar after weighting and PS matching 
compared with before (table 1). PS distributions before 
matching and PS matching are shown in figures 2 and 3, 
respectively.
No difference in risk of hospitalisation for stroke 
(ischaemic or unspecified) was found for low-strength 
DOACs or for individual products compared with 
warfarin (HR 1.00, 95% CI 0.62 to 1.62) (table 2). 
Overall, no significant difference in risk of hospi-
talisation for bleeding or haemorrhagic stroke with 
low-strength DOACs compared with warfarin was 
found. There was a significantly lower risk of haemor-
rhagic stroke with low dose apixaban compared with 
warfarin (HR 0.17, 95% CI 0.04 to 0.79).
No significant difference in risk of hospitalisation for 
stroke was observed between high-strength DOACs and 
warfarin (table 2). Compared with warfarin, a reduced 
risk of hospitalisation for bleeding was observed overall 
with high-strength DOACs (HR 0.63, 95% CI 0.44 to 0.89) 
and individually, for high-strength apixaban (HR 0.33, 
95% CI 0.17 to 0.65) but not rivaroxaban. No difference 
in risk of haemorrhagic stroke was observed with high-
strength DOACS compared with warfarin.
For the secondary outcomes, there was no increased risk 
of MI for low-strength DOACs compared with warfarin, 
however, an increased risk was observed with low-strength 
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to 4.13) (table 3). There was a significant difference in the 
risk of death between low-strength DOACs and warfarin 
(HR 0.77, 95% CI 0.60 to 0.98), however, no difference 
for the individual DOACS was observed (table 3). For 
high-strength DOACs, no difference in risk of MI was 
observed compared with warfarin (table 3). The risk of 
death was significantly reduced overall with high-strength 
DOACs (HR 0.40, 95% CI 0.28 to 0.58) and individually, 
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for apixaban (HR 0.25, 95% CI 0.11 to 0.55) and rivarox-
aban (HR 0.60, 95% CI 0.39 to 0.90).
In the post hoc analysis, a significantly increased risk of 
MI with low-strength apixaban compared with warfarin 
was found only in those not concomitantly dispensed 
aspirin at baseline (HR 2.31, 95% CI 1.08 to 4.92). For 
those on aspirin at baseline, there was no significant 
difference in risk of MI between low-strength apixaban 
and warfarin (HR 2.12, 95% CI 0.77 to 5.88) (data not 
shown).
Results of the PS-matched sensitivity analysis for the 
primary (table 4) and secondary endpoints (table 5) 
were consistent with those of the IPTW analysis. Compar-
isons of baseline covariates in the PS-matched cohort are 
described in online supplementary appendix table C.
DIsCussIOn
Both low-strength and high-strength DOACs were 
similar to warfarin in terms of effectiveness, that is risk 
of ischaemic stroke. Risk of hospitalisation for bleeding 
was significantly reduced with high-strength DOACs 
compared with warfarin while no difference was observed 
for low-strength DOACs compared with warfarin. Our use 
of the IPTW and PS matching approaches meant that we 
were able to compare outcomes in patients initiated on 
low-strength or high-strength products to similar patients 
using warfarin. Stratification of results by DOAC strength 
is important as differences were observed between 
patients initiated on low-strength and high-strength 
DOACs, likely to be reflective of physicians’ consider-
ations of risk factors of both benefits and potential harms. 
Patients initiating low-strength DOACs were on average 
a decade older and had higher CHADS2 scores than 
those on high-strength DOACs. These results suggest 
that recommendations for appropriate dosing appear 
to be adhered to in practice, and that patients at high 
risk of bleeding are likely prescribed low-strength DOACs 
rather than high strength. Our results need to be inter-
preted within the context of our study design, which was 
not intended to examine differences in outcomes specif-
ically between high-strength and low-strength DOAC 
products, but rather, to compare the outcomes associated 
with high-strength or low-strength DOACs separately to 
similar patients who initiated warfarin.
Our results for high-strength DOACs are similar to a 
meta-analysis of randomised controlled trials (RCT) which 
found a reduced risk of ischaemic stroke and a lower 
risk of mortality for DOACs compared with warfarin; 
however, this meta-analysis did not differentiate between 
low-strength and high-strength products or the risk of 
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bleeding with different strengths.16 A study comparing 
results of 10 observational studies using PS adjustment 
with results from five RCTs found no difference in the esti-
mates between RCTs and observational studies. This study 
found RCT and observation study results were similar 
with both finding a significantly reduced risk of ischaemic 
stroke with DOACs and no difference in the risk of major 
bleed.17 Neither of these studies examined outcomes of 
DOACs with warfarin separately for high-strngth and 
low-strength products. A Danish observational study 
investigating low-strength formulations18 found no differ-
ence in the risk of ischaemic stroke or bleeding between 
the low-strength DOACs and warfarin. An analysis of 
two UK primary care databases19 found no difference 
in the risk of ischaemic stroke with lower dose products 
but found a reduced risk of major bleed with lower dose 
apixaban. Additionally, in that study,19 higher doses of 
apixaban were associated with lower risk of major bleed 
with no difference in risk of ischaemic stroke compared 
with warfarin. In our study, we found no difference in risk 
of hospitalisation for ischaemic stroke or bleeding with 
low-strength DOACs. These data suggest that the bene-
fits of DOACs demonstrated in RCTs, where the majority 
of patients were prescribed the higher doses, may not 
be applicable in real-life use, where a larger number of 
patients are suitable for the lower doses.
Our result of an increased risk of MI for low-strength 
apixaban should be examined further. Our post hoc 
analysis suggests it is possible that the concomitant use 
of other antiplatelet medicines such as aspirin may 
contribute to observed differences in risks. Use of aspirin 
at baseline was similar across our study treatment groups 
with over one-third of all patients using concurrent 
aspirin, however, an significantly increased risk of MI was 
only found with low-dose apixaban in those patients who 
were not concomitantly dispensed aspirin. Evidence of 
the efficacy of low-dose apixaban is not well established, 
with only 4.9% of subjects (428 subjects) randomised to 
low-dose apixaban in clinical trials.3 In the absence of 
concomitant antiplatelet treatment low-dose apixaban 
may be insufficient to protect against the risk of MI.
A strength of our study is our use of a sequential cohort 
approach with cohorts determined by 4-month calendar 
periods. This approach was used to minimise channel-
ling bias, in which early initiators of DOACs were very 
different to warfarin initiators in the same period and 
a PS model was estimated in each calendar cohort to 
ensure comparability between treatment groups within 
each calendar period.4 20 We used an IPTW approach to 
determine ATE, reflecting the average effect at the popu-
lation level. Weighting creates a pseudo population where 
the baseline covariates are independent of treatment. 
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Additionally, PS matching was used as a sensitivity analysis 
finding similar results with the exception of bleeding risk, 
which was found to be lower with high-strength DOACs 
in the weighted analysis but not different in the matched 
analysis. Regardless of the method used to account for 
confounding, we did not observe a significantly increased 
risk of bleeding with DOACs compared with warfarin.
A limitation of our analysis was that we were unable to 
determine the dose of DOAC consumed by the patient 
as the data only contain information on the strength 
dispensed. Because of the fixed dosing recommendations 
for DOACS, the strengths dispensed likely to reflect the 
doses consumed. Additionally, we were unable to deter-
mine the indication for anticoagulant use. To minimise 
misclassification, we excluded patients with a recent 
hip or knee replacement surgery who may have been 
treated with DOACS for deep-vein thrombosis (DVT) 
prophylaxis. We were unable to specifically exclude use of 
DOACs for treatment of DVT. We identified our outcome 
events through administrative hospital claims, therefore, 
we were unable to validate our outcomes as we do not 
have access to hospital records. Another limitation is 
that variables used in the PS estimation were restricted 
to those available in the data source hence some residual 
confounding may remain.
Our study, performed in the Australian veteran popu-
lation, is likely to be generalisable to the older popula-
tion with AF, however, may not be generalisable to other 
healthcare settings and patient populations. Previous 
research has reported that there was no difference in use 
of practitioners, health services and treatment between 
veteran and non-veteran patients in both the primary and 
tertiary Australian care sectors after adjustment for age, 
service-related disability and marital status.21 We focused 
on incident users of anticoagulants and those with prior 
warfarin use were excluded. Further research should 
examine the safety and effectiveness of DOACs in popu-
lations switching from warfarin. The limited use of high-
strength dabigatran meant we were unable to determine 
outcomes of this treatment. Additionally, a number of 
hospitalisation outcome events were small, particularly 
for haemorrhagic stroke, and consequently confidence 
intervals were wide. Ongoing monitoring of the safety of 
DOACs will be required as larger populations are exposed 
to these medicines.
In conclusion, our analysis of patients initiated on antico-
agulant treatment, indicated that both high-strength and 
low-strength DOACs were similarly effective as warfarin 
in the prevention of stroke. High-strength DOACs were 
associated with a reduced bleeding risk, however, this 
appeared to be limited to high-strength apixaban, which 
is consistent with clinical trial evidence. Our significantly 
reduced risk of hospitalisation for bleeding with high-
strength products is likely explained by appropriate selec-
tion of lower risk patients for the high-strength products. 
The similar rate of bleeding events with low-strength 
DOACS and warfarin likely reflects the high baseline risk 
of bleeds in those indicated for low-strength treatment. 
Our finding of an increased risk of MI for low-strength 
apixaban requires further exploration.
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